Protox completes enrollment for Phase II benign prostatic hyperplasia study

Protox Therapeutics, a developer of receptor targeted fusion proteins, has completed enrollment of patients for its Phase II study of PRX302 in males with moderate to severe benign prostatic hyperplasia, a common and bothersome urological condition that is said to affect more than one million men in Canada and over 50 million men worldwide.